GRAL
GRAIL, Inc. Common StockGRAL
GRAL
About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
Employees: 1,170
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
106% more call options, than puts
Call options by funds: $9.3M | Put options by funds: $4.51M
68% more capital invested
Capital invested by funds: $280M [Q3] → $472M (+$192M) [Q4]
44% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 50
8.08% more ownership
Funds ownership: 70.61% [Q3] → 78.68% (+8.08%) [Q4]
3% more funds holding
Funds holding: 303 [Q3] → 312 (+9) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
7% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 76
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
61%
downside
Avg. target
$16
61%
downside
High target
$16
61%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Morgan Stanley Tejas Savant 22% 1-year accuracy 4 / 18 met price target | 61%downside $16 | Equal-Weight Initiated | 27 Nov 2024 |
Financial journalist opinion
Based on 6 articles about GRAL published over the past 30 days
Neutral
PRNewsWire
23 hours ago
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m.
Neutral
Seeking Alpha
1 day ago
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Neutral
PRNewsWire
1 day ago
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif. , Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates.
Neutral
PRNewsWire
1 week ago
GRAIL to Announce Fourth Quarter 2024 Financial Results
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025.
Neutral
PRNewsWire
1 week ago
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J.
Positive
Investopedia
3 weeks ago
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
Positive
Investopedia
1 month ago
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading.
Neutral
PRNewsWire
1 month ago
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology.
Neutral
PRNewsWire
2 months ago
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. , Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P.
Positive
MarketBeat
2 months ago
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close.
Charts implemented using Lightweight Charts™